The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients
ConditionMCI
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age55+
SponsorBeni-Suef University
About this trial
The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.
Eligibility criteria
Qualifiers
T2DM adult subjects (>55 years old) will be eligible to participate.
Patients should be taking SGLT2Is+metformin or DDP4Is + metformin for at least 1 year to be eligible.
Disqualifiers
None
Trial design
Treatments tested in this trial
- SGLT2 Is+METFORMIN
- DPP4 Is+metformin
- Control group
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov